ERIS Lifesciences Ltd

ERIS Lifescience Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

ERIS Lifesciences Ltd

₹ 870 0.36%
18 Apr - close price
eris.co.in BSE: 540596 NSE : ERIS
About

ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]

Key Points

Product Offerings
The company offers 350+ pharmaceutical products/ formulations in the Indian pharmaceutical market.[1] It is a pure-play domestic branded formulations company with no export presence.[2]

Website BSE NSE
  • Market Cap ₹ 11,840 Cr.
  • Current Price ₹ 870
  • High / Low ₹ 972 / 602
  • Stock P/E 34.0
  • Book Value ₹ 180
  • Dividend Yield 0.84 %
  • ROCE 20.3 %
  • ROE 19.0 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 22.0%

Cons

  • The company has delivered a poor sales growth of 11.8% over past five years.
  • Tax rate seems low
  • Debtor days have increased from 47.2 to 62.9 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
287 257 306 323 305 282 329 355 332 315 411 410 324
184 163 184 186 182 181 203 214 206 203 256 265 250
Operating Profit 103 94 123 137 123 102 126 141 126 111 156 144 74
OPM % 36% 37% 40% 42% 40% 36% 38% 40% 38% 35% 38% 35% 23%
3 3 6 8 6 9 3 6 3 4 4 7 3
Interest 0 0 0 1 1 1 7 7 3 3 7 7 15
Depreciation 9 10 11 12 14 15 15 16 16 17 20 25 28
Profit before tax 97 86 117 132 114 95 107 124 110 96 133 120 35
Tax % 9% 20% 9% 10% 9% 8% 11% 7% 10% 8% 16% 2% 9%
89 69 107 120 104 87 96 115 99 88 111 118 32
EPS in Rs 6.53 5.11 7.86 8.81 7.66 6.38 7.03 8.47 7.31 6.46 8.14 8.66 2.33
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
286 417 520 548 605 713 761 897 1,020 1,109 1,216 1,331 1,460
224 325 436 437 435 442 445 562 661 691 727 825 974
Operating Profit 61 92 84 111 171 271 316 334 359 417 488 506 486
OPM % 22% 22% 16% 20% 28% 38% 42% 37% 35% 38% 40% 38% 33%
3 1 9 7 3 25 28 32 11 10 25 16 19
Interest 0 0 0 0 0 1 10 23 2 1 3 21 31
Depreciation 2 2 4 15 20 21 22 32 45 38 51 65 91
Profit before tax 62 90 89 103 154 274 312 312 324 389 459 437 383
Tax % 30% 27% 27% 19% 10% 9% 6% 8% 10% 10% 9% 9%
43 66 65 83 138 248 294 285 291 351 417 398 348
EPS in Rs 3,148.36 4,785.45 4,738.18 6,060.36 10,034.18 18.05 21.36 20.75 21.45 25.82 30.69 29.27 25.59
Dividend Payout % 0% 0% 0% 0% 61% 0% 0% 0% 13% 21% 20% 25%
Compounded Sales Growth
10 Years: 12%
5 Years: 12%
3 Years: 9%
TTM: 12%
Compounded Profit Growth
10 Years: 20%
5 Years: 6%
3 Years: 11%
TTM: -12%
Stock Price CAGR
10 Years: %
5 Years: 7%
3 Years: 14%
1 Year: 41%
Return on Equity
10 Years: 27%
5 Years: 23%
3 Years: 22%
Last Year: 19%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 0 0 0 0 0 14 14 14 14 14 14 14 14
Reserves 53 119 184 267 305 561 854 1,142 1,286 1,562 1,905 2,208 2,438
1 0 0 1 0 0 376 176 0 0 0 317 597
41 55 83 86 96 82 126 138 183 179 232 245 297
Total Liabilities 96 174 268 354 402 657 1,370 1,470 1,483 1,755 2,150 2,784 3,345
11 15 64 61 65 92 490 484 601 584 642 898 1,207
CWIP 0 0 0 0 0 0 0 3 4 2 3 0 0
Investments 19 58 98 182 206 381 546 580 320 531 778 997 992
66 101 106 110 131 184 335 403 558 638 728 889 1,146
Total Assets 96 174 268 354 402 657 1,370 1,470 1,483 1,755 2,150 2,784 3,345

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
29 40 90 92 133 210 236 216 265 395 369 322
-22 -41 -85 -94 -45 -199 -593 2 127 -348 -268 -513
-7 -1 -0 1 -84 -18 363 -221 -334 -81 -88 194
Net Cash Flow 1 -1 5 -1 4 -6 7 -2 58 -34 13 3

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 18 15 16 16 15 21 29 31 50 37 41 63
Inventory Days 141 193 130 181 156 161 194 206 145 119 155 98
Days Payable 91 71 93 121 88 86 266 207 200 159 177 128
Cash Conversion Cycle 68 137 52 75 84 97 -43 30 -4 -3 19 33
Working Capital Days 23 40 11 13 8 31 2 -22 58 65 80 82
ROCE % 105% 56% 44% 53% 62% 35% 26% 24% 27% 27% 20%

Shareholding Pattern

Numbers in percentages

4 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
52.69% 52.68% 52.66% 52.66% 52.30% 52.29% 52.70% 52.86% 52.86% 54.91% 54.90% 54.90%
13.49% 13.60% 13.34% 13.31% 15.35% 15.39% 15.50% 14.86% 13.78% 13.20% 13.13% 14.27%
10.05% 9.94% 10.37% 10.50% 10.66% 10.69% 9.95% 10.02% 10.73% 14.52% 14.55% 15.63%
23.77% 23.78% 23.62% 23.52% 21.69% 21.63% 21.85% 22.27% 22.63% 17.37% 17.41% 15.19%
No. of Shareholders 46,47749,83354,22357,06151,63948,05546,74645,93144,16942,24546,49651,753

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls